Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hereditary angioedema
Biotech
BioCryst ends internal programs in pivot to partnerships
BioCryst is shuttering all internal discovery programs to focus on external innovation and partnerships.
Will Maddox
Jun 29, 2026 10:30am
Intellia touts ‘paradigm-shifting’ HAE data
Jun 15, 2026 10:37am
Intellia races in vivo CRISPR therapy to FDA after phase 3 win
Apr 27, 2026 9:24am
Pharvaris clocks a pivotal win in race for rapid HAE relief
Dec 3, 2025 9:10am
BioCryst inks $700M Astria deal to rival Takeda in rare disease
Oct 14, 2025 10:30am
Kaken strengthens late-stage HAE portfolio with $32M Astria deal
Aug 6, 2025 10:21am
